Literature, news and videos pertinent to
The Bailey Tra
Research Advocacy Program
Primary spinal cord glioblastoma: A rare cause of paraplegia
Surg Neurol Int. 2022; 13: 160.
Published online 2022 Apr 22. doi: 10.25259/SNI_135_2022

Review Article
Spine and Spinal Cord Tumors DSPN-Neurospine Special Issue
Glioma Immunotherapy: Advances and Challenges for Spinal Cord Gliomas

Neurospine 2022;19(1):13-29.
Published online: February 2, 2022

Types of Brain and Spinal Cord Tumors in Adults

Diffuse Midline Gliomas Diagnosis and Treatment

Vulnerability in Brain Tumors May Open Door to New Treatments

September 26, 2022, by Edward Winstead
Glioblastoma cells feed off injury
FRANK J. ATTENELLOAuthors Info & Affiliations
4 Jul 2018
Vol 10, Issue 448
DOI: 10.1126/scitranslmed.aau1971
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 (rQNestin)

Research reveals potential targets for therapeutic development for glioblastoma

LAB REPORT Ian Demsky September 29, 2021 11:44 AM
Glioma subtype may hold the secret to the success of immunotherapies
A common mutation in gliomas sensitizes them to immunotherapy, a finding which researchers believe could have broader therapeutic implications for all glioma patients.
Critical information about the size and growth speed of gliomas
Date: October 7, 2022
Source: Mayo Clinic
Summary: An important new clue for preventing and treating brain tumors known as gliomas has been identified. The study provides a rare window into the biological changes behind glioma development.
Dynamic cells linked to brain tumor growth and recurrence
In mice, researchers have discovered the presence of oncostreams, highly active cells connected to how brain tumors grow and invade healthy tissue
Date: June 28, 2022
Source: Michigan Medicine - University of Michigan


powered by Surfing Waves

The Bailey Tra Research Advocacy Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.

Guidestar Platinum Seal of Transparency 2021

Federal Tax I.D.: EIN 86-0818253